Rapamycin-filgrastim combination therapy ameliorates portal hypertension-induced splenomegaly: Role of β actin and S100A9 proteins modulation

Document Type : Original Article


1 Medical Histology and Cell Biology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt

2 Biochemistry Division, Chemistry Department, Faculty of Science, Zagazig University, Zagazig, Egypt


Objective(s): Thioacetamide (TAA) was administered to induce an animal model of liver disease with secondary splenomegaly to assess the mechanisms underlying the effects of rapamycin and filgrastim when taken separately or in combination on the biochemical and histopathological aspects of the liver and spleen. 
Materials and Methods: Thirty adult male albino rats were divided into five groups (control, TAA-treated group, TAA+rapamycin, TAA+filgrastim, and TAA+rapamycin+filgrastim group). We measured relative liver and spleen weights, serum levels of alanine transaminase (ALT), aspartate transaminase (AST), and albumin. Molecular docking modeling and histopathological examination of liver and spleen sections with hematoxylin and eosin and Masson trichrome staining with immunohistochemical detection of splenic CD3 and CD20 lymphocytes, S100A9 and β actin antibodies were detected. Morphometric and statistical analyses of the results were performed. 
Results: TAA administration altered the histological structure of the liver and spleen and impaired liver function. It increased the expression of splenic CD3, CD20 lymphocytes, and S100A9 while diminishing the expression of β actin. Each of rapamycin and filgrastim, when administered separately, improved liver and spleen indices and liver function, but rapamycin did not affect the albumin level. They lowered splenic B and T lymphocyte levels. Expression levels of S100A9 showed down-regulation while β actin levels were up-regulated when compared with TAA. Combination therapy improved liver and spleen tissue pathology and significantly ameliorated the expression of splenic lymphocytes through regulation of S100A9 and β actin expression. 
Conclusion: The synergistic effect of combination therapy was dependent on the regulation of splenic S100A9 and β actin levels.


Strickland GT, Elhefni H, Salman T, Waked I, Abdel-Hamid M, Mikhail NN, et al. Role of hepatitis C infection in chronic liver disease in Egypt. Am J Trop Med Hyg 2002; 67: 436-442.
Mejias M, Garcia-Pras E, Gallego J, Mendez R, Bosch J, Fernandez M. Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. J Hepatol 2010; 52: 529-539.
Lv Y, Yee Lau W, Wu H, Han X, Gong X, Liu N, et al. Causes of peripheral cytopenia in hepatitic cirrhosis and portal hypertensive splenomegaly. Exp Biol Med 2017; 242: 744-749.
Fang JJ, Zhu ZY, Hui D, Zheng GQ, Teng AG, Liu AJ. Effect of spleen lymphocytes on the splenomegaly in hepatocellular carcinoma-bearing mice. Biomed Environ Sci 2014; 27: 17-26.
Lv Y, Lau WY, Li Y, Deng J, Han X, Gong X, et al. Hypersplenism: history and current status. Exp Ther Med 2016; 12: 2377-2382.
Dwivedi D, Jena GB. THU-074-anti-fibrotic effect of dimethyl fumarate on rat liver fibrosis induced by thioacetamide: role of NF-kappa B, NLRP3, Nrf2 and autophagy. J Hepatol 2019; 70: 191-192.
Wallace MC, Hamesch K, Lunova M, Kim Y, Weiskirchen R, Strnad P, et al. Standard operating procedures in experimental liver research: thioacetamide model in mice and rats. Lab Anim 2015; 49: 21-29.
Gummert JF, Ikonen T, Morris RE. Newer immunosuppressive drugs: a review. J Am Soc Nephrol 1999; 10: 1366-1380.
Wang W, Yan J, Wang H, Shi M, Zhang M, Yang W, et al. Rapamycin ameliorates inflammation and fibrosis in the early phase of cirrhotic portal hypertension in rats through inhibition of mTORC1 but not mTORC2. PloS One 2014; 9: 83908-83922.
Pandrea I, Landay AL. Implications for therapy. Biochem Lett 2012; 18: 81-132.
Vicary GW, Roman J. Targeting the mammalian target of rapamycin in lung cancer. Am J Med Sci 2016; 352: 507-516.
Li J, Kim SG, Blenis J. Rapamycin: One drug, many effects. Cell Metab 2014; 19: 373-379.
Dale DC, Crawford J, Klippel Z, Reiner M, Osslund T, Fan E, et al. A systematic literature review of the efficacy, effectiveness, and safety of filgrastim. Support Care Cancer 2018; 26: 7-20.
Frampton JE, Lee CR, Faulds D. Filgrastim. a review of its pharmacological properties and therapeutic efficacy in neutropenia. Drugs 1994; 48: 731-760.
Azam S, Eliwan H, Hago FE. Neupogen (filgrastim) induced acute hematuria/proteinuria with 3 days of use in a 7-year-old boy diagnosed as aplastic anemia. Dr Sulaiman Al Habib Medical J 2020; 2: 92-94.
Simiczyjew A, Mazur AJ, Dratkiewicz E, Nowak D. Involvement of beta- and gamma-actin isoforms in actin cytoskeleton organization and migration abilities of bleb-forming human colon cancer cells. PloS One 2017; 12: 173709-173731.
Khaitlina SY. Functional specificity of actin isoforms. Int Rev Cytol 2001; 202:35-98.
Bunnell TM, Burbach BJ, Shimizu Y, Ervasti JM. Beta-actin specifically controls cell growth, migration, and the G-actin pool. Mol Biology Cell 2011; 22: 4047-4058.
Sedaghat F, Notopoulos A. S100 protein family and its application in clinical practice. Hippokratia 2008; 12: 198-204.
Kim HJ, Chang KA, Ha TY, Kim J, Ha S, Shin KY, et al. S100A9 knockout decreases the memory impairment and neuropathology in crossbreed mice of Tg2576 and S100A9 knockout mice model. PloS One 2014; 9: 88924-88933.
Kallberg E, Tahvili S, Ivars F, Leanderson T. Induction of S100A9 homodimer formation in vivo. Biochem Biophys Res Commun 2018; 500: 564-568.
Kim KH, Yeo SG, Yoo BC, Myung JK. Identification of calgranulin B interacting proteins and network analysis in gastrointestinal cancer cells. PloS One 2017; 12:171232-171251.
Simamora P, Alvarez JM, Yalkowsky SH. Solubilization of rapamycin. Int J Pharm 2001; 213: 25-29.
Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xenografts to fractionated radiation therapy. Cancer Res 2002; 62: 7291-7297.
Hackstein H, Taner T, Logar AJ, Thomson AW. Rapamycin inhibits macropinocytosis and mannose receptor-mediated endocytosis by bone marrow-derived dendritic cells. Blood 2002; 100: 1084-1087.
National Institute of Health (NIH). Guide for the care and use of laboratory animals. USA: National Academies; 1985. p. 23-85.
Al-Malaak MK. Histopathological changes on splenomegaly induced in experimental rats Wistar albino. Al-Qadisiah Med J 2014; 10: 50-62.
Kiang JG, Zhai M, Liao P-J, Bolduc DL, Elliott TB, Gorbunov NV. Pegylated G-CSF inhibits blood cell depletion, increases platelets, blocks splenomegaly, and improves survival after whole-body ionizing irradiation but not after irradiation combined with burn. Oxid Med Cell Longev 2014; 2014: 481392-481402.
Tietz N. Clinical guide to laboratory tests. Philadelphia, PA: WB Saunders company; 1995. p. 518-522. 
Hua F, Zhou P, Wu HY, Chu GX, Xie ZW, Ba GH. Inhibition of α-glucosidase and α-amylase by flavonoid glycosides from Lu’an GuaPian tea: molecular docking and interaction mechanism. Food Funct 2018; 9: 4173–4183.
Maier JK, Labute P. Assessment of fully automated antibody homology modeling protocols in molecular operating environment. Proteins 2014; 82: 1599-1610.
Bancroft J, Layton C. The hematoxylin and eosin In: Suvarna S.  Theory Practice of histological techniques, 7th ed edn Philadelphia: Churchill Livingstone of Elsevier, Philadelphia: Churchill Livingstone of El Sevier2013. p. 172–214.
Ramos-Vara JA, Kiupel M, Baszler T, Bliven L, Brodersen B, Chelack B, et al. Suggested guidelines for immunohistochemical techniques in veterinary diagnostic laboratories. J Vet Diagn Invest 2008; 20: 393-413.
Petrie A, Sabin C. Basic techniques for analysing data. In: M. S, K. M, editors. Medical Statistics at a Glance. 2nd ed. USA: Blackwell Publishing LTD; 2005. p. 55–56.
Gomaa A, Allam N, Elsharkawy A, El Kassas M, Waked I. Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepat Med 2017; 9: 17-25.
El-Baz FK, Salama A, Salama RAA. Therapeutic effect of dunaliella salina microalgae on thioacetamide- (TAA-) induced hepatic liver fibrosis in rats: role of TGF-β and MMP9. BioMed Res Int 2019; 2019 :1-9.
Hadeer A, AL-Kaisie BI. Pathological and biochemical study on liver of male mice intoxicated with thioacetamide. J Entomol Zool Stud 2018; 6: 1436-1441.
Chen TM, Subeq YM, Lee RP, Chiou TW, Hsu BG. Single dose intravenous thioacetamide administration as a model of acute liver damage in rats. Int J Exp Pathol 2008; 89: 223-231.
Lin Y-Y, Hu C-T, Sun D-S, Lien T-S, Chang H-H. Thioacetamide-induced liver damage and thrombocytopenia is associated with induction of antiplatelet autoantibody in mice. Sci Rep 2019; 9:17497-17508.
Mir A, Anjum F, Riaz N, Iqbal H, Wahedi HM, Khattak JZK, et al. Carbon tetrachloride (CCl4)-induced hepatotoxicity in rats: curative role of solanum nigrum. J Med Plants Res 2010; 4: 2525-2532.
Chen Y, Wang W, Wang H, Li Y, Shi M, Li H, et al. Rapamycin attenuates splenomegaly in both intrahepatic and prehepatic portal hypertensive rats by blocking mTOR signaling pathway. PloS One 2016; 11: 141159-141176.
Yang W, Shao L, Zhu S, Li H, Zhang X, Ding C, et al. Transient inhibition of mTORC1 signaling ameliorates irradiation-induced liver damage. Front Physiol 2019; 10: 228-240.
Patsenker E, Schneider V, Ledermann M, Saegesser H, Dorn C, Hellerbrand C, et al. Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. J Hepatol 2011; 55: 388-398.
Chou YY, Gao JI, Chang SF, Chang PY, Lu SC. Rapamycin inhibits lipopolysaccharide induction of granulocyte-colony stimulating factor and inducible nitric oxide synthase expression in macrophages by reducing the levels of octamer-binding factor-2. FEBS J 2011; 278: 85-96.
Chavez-Tapia NC, Mendiola-Pastrana I, Ornelas-Arroyo VJ, Norena-Herrera C, Vidana-Perez D, Delgado-Sanchez G, et al. Granulocyte-colony stimulating factor for acute-on-chronic liver failure: systematic review and meta-analysis. Ann Hepatol 2015; 14: 631-641.
Stiff PJ, Bensinger W, Abidi MH, Gingrich R, Artz AS, Nademanee A, et al. Clinical and ultrasonic evaluation of spleen size during peripheral blood progenitor cell mobilization by filgrastim: results of an open-label trial in normal donors. Biol Blood Marrow Transplant 2009; 15: 827-834.
Masood N, Shaikh AJ, Memon WA, Idress R. Splenic rupture, secondary to G-CSF use for chemotherapy induced neutropenia: a case report and review of literature. Cases J 2008; 1: 418-421.
Zheng Y, Collins SL, Lutz MA, Allen AN, Kole TP, Zarek PE, et al. A role for mammalian target of rapamycin in regulating T cell activation versus anergy. J Immunol 2007; 178: 2163-2172.
Ye L, Lee J, Xu L, Mohammed A-U-R, Li W, Hale JS, et al. MTOR promotes antiviral humoral immunity by differentially regulating CD4 helper T cell and B cell responses. J Virol 2017; 91: 1653-1670.
Simler NR, Howell DCJ, Marshall RP, Goldsack NR, Hasleton PS, Laurent GJ, et al. The rapamycin analogue SDZ RAD attenuates bleomycin-induced pulmonary fibrosis in rats. Eur Res J 2002; 19: 1124-1127.
Martins A, Han J, Kim SO. The multifaceted effects of granulocyte colony-stimulating factor in immunomodulation and potential roles in intestinal immune homeostasis. IUBMB Life 2010; 62: 611-617.
Ishizuka K, Fujii W, Azuma N, Mizobuchi H, Morimoto A, Sanjoba C, et al. Pathological roles of MRP14 in anemia and splenomegaly during experimental visceral leishmaniasis. PLoS Negl Trop Dis 2020; 14: 1-16.
Spangler W, Kass PH. Pathologic and prognostic characteristics of splenomegaly in dogs due to fibrohistiocytic nodules: 98 cases. Vet Pathol 1998; 35: 488-498.
Mesa ML, Carrizosa R, Martinez‐Honduvilla C, Benito M, Fabregat I. Changes in rat liver gene expression induced by thioacetamide: protective role of S‐adenosyl‐L‐methionine by a glutathione‐dependent mechanism. Hepatology 1996; 23: 600-606.
Love JM, Bober BG, Orozco E, White AT, Bremner SN, Lovering RM. MTOR regulates peripheral nerve response to tensile strain.  J Neurophysiol 2017; 117: 2075-2084.
Schaub T, Gürgen D, Maus D, Lange C, Tarabykin V, Dragun D, et al. MTORC1 and mTORC2 differentially regulate cell fate programs to coordinate osteoblastic differentiation in mesenchymal stromal cells. Sci Rep 2019; 9: 1-19.
Speranza L, Giuliano T, Volpicelli F, De Stefano ME, Lombardi L, Chambery A, et al. Activation of 5-HT7 receptor stimulates neurite elongation through mTOR, Cdc42 and actin filaments dynamics. Front Behav Neurosci 2015; 9: 62-76.
Zhang Y, Zhang JW, Lv GY, Xie SL, Wang GY. Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells. Int J Med Sci 2012; 9:216-224.
Liu R, Iadevaia V, Averous J, Taylor PM, Zhang Z, Proud CG. Impairing the production of ribosomal RNA activates mammalian target of rapamycin complex 1 signalling and downstream translation factors. Nucleic Acids Res 2014; 42:5083-5096.
Eliseeva I, Vasilieva M, Ovchinnikov LP. Translation of human beta-actin mRNA is regulated by mTOR pathway. Genes 2019; 10:1-12.
Izdebska M, Grzanka D, Gagat M, Gackowska L, Grzanka A. The effect of G-CSF on F-actin reorganization in HL-60 and K562 cell lines. Oncol Rep 2012; 28:2138-2148.